Purification and Formulation of Cannabinoids (CBD)

Purification and Formulation of Cannabinoids (CBD)
Product Description

Grace has developed and introduced a patented silica based carrier, SYLOID® XDP silica, to directly convert liquid ingredients such as CBD into solid dosage forms. Extracting and purifying CBD from the hemp plant is a multi-step process which focuses on removal of several undesirable impurities. Grace has a portfolio of products that can help CBD producers not only purify their product but also formulate solid dosage forms that are stable and bioavailable.

Read more Show less

W. R. Grace & Co

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

W. R. Grace & Co

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
View company profile

More Products from W. R. Grace & Co (2)

  • Custom Fine Chemical Manufacturing

    Product Custom Fine Chemical Manufacturing

    Our comprehensive portfolio of services, integrated manufacturing, and regulatory leadership differentiates us as a leading contract development and manufacturing partner. With a proven ability to deliver solutions to complex challenges, Grace’s FCMS supports the entire small molecule development cycle fro...
  • Purification and Formulation of Oily APIs and Omega-3s

    Product Purification and Formulation of Oily APIs and Omega-3s

    Grace resins and excipients improve purity and create better targeted and higher value formulations with enhanced bioavailability. Grace is solving purification and formulation issues in oily APIs and Omega-3s in high quality separation capabilities, customization, reliability and speed to market, and ...

W. R. Grace & Co resources (2)

  • Grace Completes Acquisition of Fine Chemistry Business

    News Grace Completes Acquisition of Fine Chemistry Business

    June 01, 2021: W. R. Grace & Co. announced the completion of its acquisition of the Fine Chemistry Services business (“FCS”) of Albemarle Corporation (NYSE: ALB) for approximately $570 million, including $300 million paid in cash and $270 million funded through the issuance to Albemarle of non-participating preferred equity of a newly created Grace subsidiary.
    24 Sep 2021
  • Grace Pharmaceutical Solutions Brochure

    Brochure Grace Pharmaceutical Solutions Brochure

    Learn more about Grace's unmatched quality and reproducibility of our fine chemicals, chromatography resins, formulation excipients, and active ingredient delivery technologies.